Byoung Ryu, PhD

Byoung Ryu is the Executive Vice President of Discovery Research and Vector Biology at Umoja. Byoung brings more than two decades of experience in cell and gene therapy research and product development. Before joining Umoja, Dr. Ryu was the Vice President of Vector biology at Lyell Immunopharma where he established lentiviral vector system and manufacturing. Dr. Ryu received his Ph.D. from the University of Tennessee, Health Science Center and trained as a postdoc at St. Jude Children’s Research Hospital working on lentiviral safety for gene therapy application. He joined bluebird bio in 2010 where he developed two clinical lentiviral vectors, LentiGlobin BB305 (ZYNTEGLOTM) for b-thalassemia and Sickle Cell Disease and bb2121 CAR vector for multiple myeloma, both which are in clinical trials and under BLA licensing review at FDA.